

CURRICULUM VITAE

Name AGOSTINI Massimiliano
Date of birth 20 January 1972
Address Dept. Experimental Medicine
 University of Rome "Tor Vergata"
 via Montpellier, 1, 00133 Roma, Italy
Phone Office F485 +39 (06) 7259 6473
Phone Lab F484 +39 (06) 7259 6687
Email m.agostini@med.uniroma2.it
Twitter @agostini_massi

Associate Professor in Molecular Biology

ORCID identifier 0000-0003-3124-2072

Public record <http://orcid.org/0000-0003-3124-2072>

Scopus Author ID: 7005322176

Researcher ID: G-9579-2014 <http://www.researcherid.com/rid/G-9579-2014>

SCIENTIFIC PROFILE

Massimiliano Agostini is Associate Professor in Molecular Biology at the University of Rome "Tor Vergata". He obtained his PhD in Clinical and Experimental Pharmacology (Perugia, Italy), working on the pharmacological regulation of the immune response. In 2005, he became a Research Assistant at University of Perugia (Italy). In 2007-2014, he worked at the MRC Toxicology Unit, (UK), as PostDoc and then as Senior Investigator. In 2014 worked at TW Mak's laboratory as visiting scientist (Canada). From 2014 to 2019 Visiting Scientist, MRC Toxicology Unit, Cambridge University, UK.

MA is mainly interested in the characterization of transgenic mice with genetic alterations in the p53 family genes and their targets to understand their effect on development and cancer. In particular, he aims to investigate the role of the transcription factor ZNF750 (transcriptionally regulated by p63) in tumorigenesis by using in vitro and in vivo models combined with system biology (transcriptomics, proteomics and metabolomics). Currently, MA is mainly involved on:

- 1) To identify in-vivo functions of ZNF750 in development, physiology and tumorigenesis by using genetically modified animals.
- 2) Investigating the role of lipid droplets in physiology and pathophysiology.
- 3) Uncover novel molecular targets in lipid metabolism for cancer therapy.

EDUCATION

1997 **Degree in** Chemical and Pharmaceutical Technology
 1998 Pharmacist license, state of Italy
 2006 **PhD Studies** in Clinical and Experimental Pharmacology: Dept. Clinical and Experimental Medicine, Section of Pharmacology, University of Perugia, Italy.

CAREER HISTORY

1997-1999: Visiting Fellow Section of Pharmacology, School of Medicine, University of Perugia, Italy
1999-2001: Fellowship Section of Pharmacology, School of Medicine, University of Perugia, Italy
2005-2006 Research Assistant Section of Pharmacology, School of Medicine, University of Perugia, Italy
2006-2007 Research Assistant Section of Pharmacology, School of Medicine, University of Perugia, Italy
2007-2011 Career Development Fellow, MRC Toxicology Unit
2014-2014 Visiting Scientist, The Campbell Family Institute for Breast Cancer Research, Toronto, Canada
2011-2014 Senior Investigator, MRC Toxicology Unit
2014-2019 Visiting Scientist, MRC Toxicology Unit, Cambridge University, UK.

TEACHING ACTIVITIES

2015-Present II level Master, Personalized Nutrition: Molecular and Genetic bases, 1CFU
2016-Present I level Master, Nutrition and Cosmesis, 2CFU
2016-Present International Medical School (Molecular Biology 3CFU)
2017-Present Specialization School of Infection Disease (Molecular Biology 1CFU)
2019-Present Specialization School of Microbiology and Virology (Molecular Biology 1CFU)
2019-Present Specialization School of Endocrinology (Molecular Biology 1CFU)
2020-Present Course of Pharmacy (Biochemistry 3CFU)
2022-2024 International Medical School (Biochemistry 1CFU)

2023-Present Specialization School of Cardiovascular disease (Molecular Biology 1CFU)
2023-Present Specialization School of Pathology (Molecular Biology 1CFU)
2023-Present Human Nutrition Sciences (Nutrition, inflammation and cancer 2CFU)
2025-Present Human Nutrition Sciences (Cellular Senescence and Aging 2CFU)

OTHER

2018-Present Scientific Division Torvergata Oncoscience Research (TOR), University of Rome Tor Vergata
2019-2025 Scientific advisory committee Center for Comparative Medicine, Alternative Techniques and Aquaculture
2019-Present Teaching board member Specialization School in Endocrinology
2019-Present Teaching board member Specialization School in Infection Disease Microbiology and Virology
2019-Present Teaching board member Specialization School in Microbiology and Virology
2023-Present Teaching board member Specialization School in Cardiovascular disease
2024-Present Teaching board member Specialization School in Pathology
2025-Present Deputy Coordinator of PhD in Biochemistry and Molecular Biology

EDITORIAL EXPERIENCE

2014-2019 Editorial board of *Molecular & Cellular Oncology*
 2011-2023 Receiving Editor *Cell Death & Disease*
 2011-Present Editorial board as Review Editor of Frontiers in Oncology's speciality section *Frontiers in Cancer Molecular Targets and Therapeutics*
 2022-Present Editorial Board of *Cancers*
 2023-Present Deputy Editor *Cell Death & Disease*

Ad hoc Referee:

Cell Death & Disease, Cell Death and Differentiation, Frontiers in Cancer, Molecular and Cellular Oncology, Molecular Neurobiology, Oncogene, Oncotarget, Cell Cycle, FEBS Journal, Scientific Reports, Journal of Cellular Biochemistry, Molecular Oncology, FASEB Journal, Journal of Human Genetics, Biology Direct, Discovery Oncology

PUBLICATION

Scientific Papers	90 (First Author: 17; Corresponding Author: 16)
Citations	9643 (Scholar) 3448 (ISI) 7052 (Scopus)
h-Index	49 (Scholar) 36 (ISI) 43 (Scopus)

PUBLICATION LIST (2020-2025) (Impact Factor year of the publication)

- Agostini M***, Ganini G, Candi E and Melino G
The role of non-coding RNAs in epithelial cancer. *Cell Death Discov* 6, 13 (2020). (*) Corresponding Author [IF 4.11]
- Cassandri M, Butera A, Amelio I, Lena AM, Montanaro M, Mauriello A, Anemona L, Candi E, Knight RA, **Agostini M*** and Melino G.
ZNF750 represses breast cancer invasion via epigenetic control of prometastatic genes *Oncogene* 39, 4331–4343 (2020) (*) Corresponding Author [IF 7.97]
- Amelio I, Panatta P, Niklison-Chirou MV, Steinert J, **Agostini M**, Morone N, Knight RA, Melino G
The p73 C-terminus directs hippocampal development *Proc Natl Acad Sci U S A* 2020 117 (27) 15694-15701 [IF 9.41]
- Niklison-Chirou MV, **Agostini M***, Amelio I and Melino G
Regulation of Adult Neurogenesis in Mammalian Brain *Int. J. Mol. Sci.* 2020, 21(14), 4869; *Co-First Author [IF 4.55]
- Butera A, Cassandri M, Rugolo F, **Agostini M*** and Melino G
The ZNF750-RAC1 axis as potential prognostic factor for breast cancer *Cell Death Discov* 2020 Nov 29;6(1):135 (*) Corresponding Author [IF 4.1]
- Velletri T, Huang Y, Wang Y, Li Q, Hu M, Xie N, Yang Q, Chen X, Chen Q, Shou P, Gan Y, Candi E, Annicchiarico-Petruzzelli M, **Agostini M**, Melino G, Shi Y, Yang H and Wang Y
Loss of p53 in mesenchymal stem cells promotes alteration of bone remodelling through negative regulation of osteoprotegerin *Cell Death Differ* 2021 Jan;28(1):156-169. [IF 15.82]

7. Rugolo F, Bazan NG, Calandria J, Jun B, Raschellà G, Melino G, and **Agostini M**
The expression of ELOVL4, repressed by MYCN, defines neuroblastoma patients with good outcome *Oncogene* 2021 Sep;40(38):5741-5751 [IF 9.86]
8. Lena AM, Foffi E, **Agostini M**, Mancini M, Annicchiarico-Petruzzelli M, Aberdam D, Velletri T, Shi Y, Melino G, Wang Y and Candi E
TAp63 regulates bone remodeling by modulating the expression of TNFRSF11B/Osteoprotegerin *Cell Cycle* 2021 Nov;20(22):2428-2441 [IF 4.53]
9. **Agostini M***, Melino G, Habeb B Calandria JM and Bazan NG
Targeting lipid metabolism in cancer: neuroblastoma *Cancer Metastasis Rev* 2022 Jun 10. doi: 10.1007/s10555-022-10040-8. (*) Corresponding Author [2020 IF 9.26]
10. **Agostini M**, Mancini M and Candi E
Long non-coding RNAs affecting cell metabolism in cancer *Biol Direct.* 2022 Oct 1;17(1):26 [IF 4.78]
11. Montanaro M*, **Agostini M***, Anemona L, Bonanno E, Servadei F, Finazzi Agrò E, Asimakopoulos AD, Ganini C, Cipriani C, Signoretti M, Bove P, Rugolo F, Imperiali B, Melino G, Mauriello A, Scimeca M ZNF750: a novel prognostic biomarker in metastatic prostate cancer *Int. J. Mol. Sci.* 2023, 24, 651 *Co-First Author [IF 4.9]
12. Vitale I, Pietrocola F, Guilbaud E, Aaronson SA, Abrams JM, Dieter Adam, **Agostini M**, Agostinis P and et al. Apoptotic cell death in disease—Current understanding of the NCCD 2023 *Cell Death Differ* 2023 May;30(5):1097-1154 IF 15.82]
13. Butera A*, **Agostini M***, Cassandri M, De Nicola F, Fanciulli M, D'Ambrosio L, Falasca L, Nardacci R, Wang L, Piacentini M, Knight RA, Jia W, Sun Q, Shi Y, Wang Y, Candi E and Melino G
ZFP750 affects the cutaneous barrier through regulating lipid metabolism *Science Advances* 2023 Apr 28;9(17):eadg542 *Co-First Author [IF 11.7]
14. Scimeca M, Rovella V, Palumbo V, Scioli MP, Bonfiglio R, Anemona L, Bernassola F, Bove P, Buonomo OC, Palmieri G, Savino L, Sica GS, Smirnov A, Tisone G, Wang Y, Melino G, Piacentini M, Frati L, **Agostini M**, Candi E, Mauriello A
Programmed cell death pathways in cholangiocarcinoma: opportunities for targeted therapy *Cancers* 2023 Jul 15;15(14):3638 [IF 4.5]
15. Liu R, Scimeca M, Sun Q, Melino G, Mauriello A, Shao C, TOR Centre, Shi Y, Piacentini M, Tisone G and **Agostini M***
Harnessing metabolism of hepatic macrophages to aid liver regeneration *Cell Death Dis.* 2023 Aug 29;14(8):574 (*) Corresponding Author [IF 8.1]
16. Hou P, Fang J, Liu Z, Shi Y, **Agostini M**, Mauriello A, Federici M, Melino G & TOR Centre
Macrophages polarization and metabolism in atherosclerosis *Cell Death Dis.* 2023 Oct 20;14(10):691.[IF 8.1]
17. Li Y, Giovannini S, Wang T, Fang J, Li P, Shao C, Wang Y and TOR centre*, Shi Y, Candi E, Melino G and Bernassola F
p63: a crucial player in epithelial stemness regulation
*TOR center: **Agostini M**, Bove P, Mauriello A, Novelli G, Piacentini M, Rovella V, Scimeca M, Sica G, Sun Q and Tisone G *Oncogene* 2023 Nov;42(46):3371-3384 [IF 6.9]
18. Peng F, Zhang N, Candi E, **Agostini M**, Piacentini M, TOR Centre, Shi Y, Huang Y, and Melino G
Alleviating hypoxia to improve cancer immunotherapy *Oncogene* 2023 Dec;42(49):3591-3604 [IF 6.9]
19. Zhu M, Rovella V, Scimeca M, Mauriello A, Shi Y, Bischof J, Woodsmith J, Melino G, Tisone G, **Agostini M***
Genomic and transcriptomic profiling of hepatocellular carcinoma reveals a rare molecular subtype *Discov Oncol.* 2024 Jan 16;15(1):10. (*) Corresponding Author [IF 2.9]
20. Scimeca M, Bischof J, Bonfiglio R, Nale E, Iacovelli V, Carilli M, Vittori M, **Agostini M**, Rovella V, Servadei F, Giacobbi E, Candi E, Shi Y, Melino G, Mauriello A, Bove P.
Molecular profiling of a bladder cancer with very high tumour mutational burden *Cell Death Discovery* 2024 Apr 30;10(1):202. [IF 7.0]

21. Giovannini S, Li Y, Pecorari R, Fierro C, Fiorilli C, Corigliano F, Moriconi V, Zhou J, De Antoni A, Smirnov A, Rinalducci S, Timperio AM, **Agostini M**, Zhang J, Shi Y, Candi E, Melino G, Bernassola F.
Thioredoxin-interacting protein (TXNIP) is a substrate of the NEDD4-like E3 ubiquitin-protein ligase WWP1 in cellular redox state regulation of acute myeloid leukemia cells *Mol Oncol.* 2024 Oct 4. doi: 10.1002/1878-0261.13722. [IF 4.5]

22. **Agostini M**, Giacobbi E, Servadei F, Bishof J, Funke L, Sica G, Rovella V, Shi Y, Candi E, Melino G, Scimeca M, Mauriello A, Bove P
Unveiling the Molecular Profile of a Prostate Carcinoma: Implications for Personalized Medicine *Biol Direct* 2024 Dec 31;19(1):146. [IF 4.9]

23. Concetti L, Scimeca M, Bischof J, Woodsmith J, **Agostini M**, Fiorani C, Shi Y, Candi E, Melino G, Mauriello A, Sica G
Multi-omic characterization of CMS1 colorectal cancer with dampened immune response improves precision medicine *Mol Oncol.* 2025 Dec;19(12):3486-3498. [IF 4.5]

24. Liu R, Cao L, Zhou Y, Li Y, Wang T, Meng Z, Yang T, Feng C, Yang Q, Liu X, Chen Y, **Agostini M**, Li P, Melino G, Wang Y, Shao C and Shi Y
Spermidine Enhances Macrophages Anti-inflammatory and Regenerative Functions by Improving Mitochondrial Fitness *Phytomedicine.* 2025 Nov 25;148:157349. [IF 8.3]